These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 19949044)

  • 1. MRI as an outcome in multiple sclerosis clinical trials.
    Tenser RB
    Neurology; 2009 Dec; 73(22):1933-4; author reply 1934. PubMed ID: 19949044
    [No Abstract]   [Full Text] [Related]  

  • 2. MRI as an outcome in multiple sclerosis clinical trials.
    Sormani MP; Filippi M; De Stefano N; ; Ebers G; Daumer M
    Neurology; 2009 Dec; 73(22):1932; author reply 1932-3. PubMed ID: 19949043
    [No Abstract]   [Full Text] [Related]  

  • 3. Are magnetic resonance findings predictive of clinical outcome in therapeutic trials in multiple sclerosis? The dilemma of interferon-beta.
    McDonald WI; Miller DH; Thompson AJ
    Ann Neurol; 1994 Jul; 36(1):14-8. PubMed ID: 8024255
    [No Abstract]   [Full Text] [Related]  

  • 4. Outcome measures for clinical trials in multiple sclerosis.
    Panitch HS
    Ann Neurol; 1992 Jan; 31(1):116-7. PubMed ID: 1543345
    [No Abstract]   [Full Text] [Related]  

  • 5. Magnetic resonance imaging metrics and their correlation with clinical outcomes in multiple sclerosis: a review of the literature and future perspectives.
    Bar-Zohar D; Agosta F; Goldstaub D; Filippi M
    Mult Scler; 2008 Jul; 14(6):719-27. PubMed ID: 18424478
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Advanced magnetic resonance imaging metrics: implications for multiple sclerosis clinical trials.
    Zivadinov R
    Methods Find Exp Clin Pharmacol; 2009; 31(1):29-40. PubMed ID: 19357796
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The cost of delaying treatment in multiple sclerosis: what is lost is not regained.
    Barton J; Benatar M
    Neurology; 2002 Feb; 58(4):668; author reply 668. PubMed ID: 11922032
    [No Abstract]   [Full Text] [Related]  

  • 8. Early treatment of multiple sclerosis to prevent neurologic damage.
    Coyle PK
    Neurology; 2008 Dec; 71(24 Suppl 3):S3-7. PubMed ID: 19064872
    [TBL] [Abstract][Full Text] [Related]  

  • 9. You get what you measure: evaluating endpoints in MS clinical trials.
    Marrie RA
    Neurology; 2008 Aug; 71(9):620-1. PubMed ID: 18685132
    [No Abstract]   [Full Text] [Related]  

  • 10. Defining multiple sclerosis treatment response with magnetic resonance imaging: how much activity is too much?
    Giacomini PS; Arnold DL; Bar-Or A; Antel JP
    Arch Neurol; 2009 Jan; 66(1):19-20. PubMed ID: 19139295
    [No Abstract]   [Full Text] [Related]  

  • 11. The use of MR imaging as an outcome measure in multiple sclerosis clinical trials.
    Bermel RA; Fisher E; Cohen JA
    Neuroimaging Clin N Am; 2008 Nov; 18(4):687-701, xi. PubMed ID: 19068409
    [TBL] [Abstract][Full Text] [Related]  

  • 12. No shortcuts to outcome in MS clinical trials?
    Koch-Henriksen N
    Neurology; 2009 Feb; 72(8):686-7. PubMed ID: 19237696
    [No Abstract]   [Full Text] [Related]  

  • 13. Trial measures in multiple sclerosis: the use of magnetic resonance imaging in the evaluation of clinical trials.
    Paty DW
    Neurology; 1988 Jul; 38(7 Suppl 2):82-3. PubMed ID: 3386847
    [No Abstract]   [Full Text] [Related]  

  • 14. Expanded clinical trials of treatments for multiple sclerosis. The Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis of The National Multiple Sclerosis Society.
    Whitaker JN
    Ann Neurol; 1993 Dec; 34(6):755-6. PubMed ID: 8250523
    [No Abstract]   [Full Text] [Related]  

  • 15. Translating pathology in multiple sclerosis: the combination of postmortem imaging, histopathology and clinical findings.
    Seewann A; Kooi EJ; Roosendaal SD; Barkhof F; van der Valk P; Geurts JJ
    Acta Neurol Scand; 2009 Jun; 119(6):349-55. PubMed ID: 19254283
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Validity of brain MRI as the primary outcome criterion in multiple sclerosis phase II clinical trials.
    Liedtke W; Limmroth V
    Ann Neurol; 1996 Feb; 39(2):276-7. PubMed ID: 8967762
    [No Abstract]   [Full Text] [Related]  

  • 17. Optimisation of immunomodulatory therapies.
    Comi G
    Neurol Sci; 2005 May; 26 Suppl 1():S15-7. PubMed ID: 15883679
    [No Abstract]   [Full Text] [Related]  

  • 18. Brain atrophy as an outcome measure for multiple sclerosis clinical trials: a "no-brainer"?
    Rudick RA; Fisher E
    Neurology; 2009 Feb; 72(7):586-7. PubMed ID: 19221291
    [No Abstract]   [Full Text] [Related]  

  • 19. New MRI techniques and "aggressive" multiple sclerosis.
    Fazekas F; Thompson A
    Mult Scler; 2009 Mar; 15(3):283-4. PubMed ID: 19244394
    [No Abstract]   [Full Text] [Related]  

  • 20. Multiple sclerosis, part II: nonconventional MRI techniques. Preface.
    Filippi M
    Neuroimaging Clin N Am; 2009 Feb; 19(1):xiii-xiv. PubMed ID: 19064195
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.